Literature DB >> 2525330

Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.

M Kinoshita1, K Hashimoto, Y Ohbayashi, T Inoue, H Taguchi, K Mitsunami.   

Abstract

Nicorandil was compared with placebo, propranolol and low and high doses of diltiazem therapy in 12 patients with chronic stable angina pectoris to elucidate its antianginal mechanism. A computer-assisted treadmill exercise test was performed after administration of either placebo, 30 mg of nicorandil, 40 mg of propranolol, or low-dose 60 and high-dose 120 mg of diltiazem. Exercise duration and time to the onset of ischemia were significantly increased after each drug administration and there was no significant difference in the percent increase in exercise duration between nicorandil (44 +/- 7%), propranolol (47 +/- 11%) and high-dose diltiazem (39 +/- 5%) compared with placebo. Nicorandil increased exercise duration in patients with 1-vessel disease more effectively (7.5 +/- 0.7 minutes, p less than 0.05) than either propranolol or low-dose diltiazem (6.7 +/- 0.7, 6.1 +/- 0.9 minutes, respectively). The decrease in blood pressure obtained with nicorandil was approximately the same as that with diltiazem. Nicorandil increased exercise duration associated with higher peak double product compared with low-dose diltiazem. In contrast, high-dose diltiazem increased exercise duration at the same double product as low-dose diltiazem. Propranolol increased exercise duration at a lower level of peak double product. Because our previous study demonstrated that low-dose diltiazem yielded a plasma concentration high enough to reduce coronary tone, it appears unlikely that nicorandil will reduce coronary tone further and subsequently increased coronary reserve. Therefore, left ventricular preload reduction may be the mechanism responsible for higher values of double product obtained with nicorandil.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525330     DOI: 10.1016/0002-9149(89)90209-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Effect of the potassium-channel opener nicorandil as an adjunct to cardioplegia on myocardial preservation in isolated rabbit hearts.

Authors:  Y Wang; M Sunamori; T Yoshida
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 2.  Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.

Authors:  C Knight; H Purcell; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 3.  Management of vasospastic angina--role of nicorandil.

Authors:  J C Kaski
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 5.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

6.  Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

Authors:  K Hashimoto; M Kinoshita; Y Ohbayashi
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.